
Decoding Hippo Pathway Crosstalk: Validated Cloud-Clone Antibodies Enable Multi-pathway Interaction Research

Full-marker reagent portfolio supports mechanistic studies linking Hippo, TGF-β/BMP and WNT signalling cascades



Target	Product Core No.	Target	Product Core No.	Target	Product Core No.	Target	Product Core No.	Target	Product Core No.
ACTB	B340	BMPR1A	A015	FZD1	E571	RASSF1	J930	WNT16	P121
ACTG1	B391	BMPR1B	A730	FZD10	B832	SERPINE1	A532	WNT2	L820
AFP	A153	BMPR2	A016	FZD4	B813	SMAD1	A647	WNT2B	L819
AMH	A228	CCND1	A585	FZD6	E576	SMAD2	C124	WNT3	L818
AMOT	C296	CCND2	A586	FZD9	B816	SMAD3	C123	WNT3A	P155
APC	A738	CCND3	A587	GDF5	C110	SMAD4	B925	WNT4	L817
APC2	B996	CDH1	A017	GDF6	C111	SMAD7	A648	WNT5A	P549
AREG	A006	CRB2	N711	GDF7	C112	SOX2	A406	WNT5B	P122
AXIN1	C191	CSNK1D	D345	GSK3B	D317	STK3	H119	WNT6	P548
AXIN2	C192	CTGF	A010	ITGB2	B586	TCF7L2	P601	WNT7A	P547
BBC3	B909	CTNNA1	C201	LEF1	C215	TEAD1	M351	WNT7B	P546
BIRC2	E231	CTNNB1	B021	MPP5	A744	TGFB1	A124	WNT9B	P550
BIRC5	C045	DLG1	G169	MYC	B290	TGFB2	A218	WWC1	L824
BMP2	A013	DLG2	A680	NF2	B946	TGFB3	B949	YAP1	G547
BMP4	A014	DLG3	G764	PPP1CA	C198	TGFBR1	A397	YWHAE	J805
BMP5	C103	DLG4	G168	PPP1CB	E027	TGFBR2	C972	YWHAQ	J808
BMP6	A646	DVL1	J540	PPP2CA	E029	WNT1	L821	YWHAZ	J809
BMP7	A799	DVL2	L454	PPP2CB	E030	WNT10A	P358		
BMP8A	C104	DVL3	L453	PRKCI	A495	WNT10B	P553		
BMP8B	C105	FGF1	A032	PRKCZ	B380	WNT11	P552		

HUSTON, TX, UNITED STATES, October 20, 2026 /EINPresswire.com/ -- The Hippo signalling pathway does not operate in isolation. It forms intricate crosstalk networks with two canonical cascades: Wnt and TGF-β/BMP. This crosstalk represents a major research hotspot, and unravelling these interactive mechanisms is critical for understanding the pathogenesis of tumours, bone metabolic disorders and fibrotic conditions.

To begin with the Hippo-TGF-β/BMP axis: upon ligand stimulation, TGF-β and BMP activate cell-surface receptors, triggering SMAD1/2/3/4 transcription factors to translocate into the nucleus and regulate target-gene expression. YAP/TAZ directly binds SMAD proteins to synergistically amplify transcription of pro-fibrotic and pro-osteogenic genes. Hippo pathway inactivation leads to massive nuclear accumulation of YAP, which exaggerates TGF-β-driven tissue fibrosis. By contrast, high LATS kinase activity disrupts YAP-SMAD complex formation and suppresses pathological bone overgrowth as well as organ fibrosis. Concurrent dysregulation of both pathways serves as a core pathogenic feature in osteoporosis, osteoarthritis, hepatic and pulmonary fibrosis.

For Hippo-WNT crosstalk: WNT activation triggers nuclear translocation of β-catenin to initiate proliferative gene transcription. YAP forms a co-transcriptional complex with β-catenin to

synergistically boost tumour cell proliferation. Polarity proteins CDH1 and CTNNA1 participate in upstream regulation for both pathways. Disruption of cell-cell junctions simultaneously activates WNT signalling and dampens Hippo activity, jointly fuelling tumour invasion and metastasis. Such dual-pathway crosstalk is essential evidence for studies covering embryonic development, stem-cell proliferation and intestinal neoplasms.

(Figure 1 Core biological functions and central mechanism of the Hippo signalling pathway. The Hippo pathway governs cell proliferation and apoptosis to regulate organ size and maintain cell-number homeostasis. It mediates cell contact inhibition by sensing cell density and restraining excessive proliferation. It modulates bone metabolism and remodelling by controlling osteogenesis, osteoclastogenesis and bone repair. Aberrant YAP/TAZ activity promotes tumour-related proliferation and invasion. It cooperates with TGF-β to mediate fibrosis and matrix deposition. Core mechanism: MST1/2 → LATS1/2 → phosphorylation and nucleocytoplasmic shuttling of YAP/TAZ.)

Investigating multi-pathway crosstalk requires simultaneous measurement of core Hippo components, TGF-β/BMP members, and upstream/downstream WNT markers. This calls for broad target coverage and multi-assay compatibility. Poor target selection or technique-limited antibodies can disrupt workflows and produce incomplete mechanistic data. Cloud-Clone's products cover 97 targets at key nodes of these interconnected pathways to support mechanistic studies of multi-pathway crosstalk.

(Figure 2 List of Hippo pathway-related targets from Cloud-Clone, including core catalogue numbers for each biomarker.)
This product suite includes core Hippo molecules such as YAP, TAZ, MST and LATS; complete TGF-β/BMP targets including TGFB1/2/3, SMAD1-4 and BMP2/4/6/7; as well as full WNT regulatory proteins: WNT1/3A/4/11, CTNNB1, AXIN1/2 and the complete FZD family. All antibodies have undergone practical multi-platform validation, supporting quantitative Western blot on cell lysates, immunohistochemical localisation in tissue sections, immunofluorescence co-localisation and flow-cytometry-based protein quantification.
For co-localisation assays, Cloud-Clone AF488- and FITC-conjugated secondary antibodies pair with pathway-specific primary antibodies. Researchers can label YAP and β-catenin within the same cell to directly visualise their nuclear co-localisation and validate pathway synergy. Flow cytometry enables parallel quantification of multiple pathway proteins and is compatible with Luminex and CBA multiplex assays, permitting high-throughput profiling of numerous targets from limited sample input.
Cloud-Clone antibodies are validated for human, mouse, rat, porcine, bovine and other model organisms, suiting human clinical samples, gene-edited mouse models and large-animal translational research. Monoclonal antibodies deliver high specificity for flow cytometry and quantitative Western blot applications, while polyclonal antibodies offer strong affinity for staining low-abundance proteins in tissue samples. Matching recombinant proteins and ELISA kits are also available, enabling end-to-end workflows from protein qualitative localisation to precise sample quantification.

As an original reagent manufacturer performing full in-house production, Cloud-Clone provides complete traceable validation datasets for all products to reduce experimental trial-and-error costs. This comprehensive biomarker portfolio enables researchers to build solid, logically consistent regulatory models and generate reliable experimental evidence for multi-pathway interaction projects.

About Cloud-Clone Corp.
Cloud-Clone Corp. is dedicated to the development and production of high-quality immunoassay reagents and detection solutions. With a focus on antibody engineering, multiplex assay development, and cross-platform compatibility, the company provides research tools designed to support precision medicine and advanced biomedical investigation globally. Our core products and services include the research and development of proteins, antibodies, ELISA kits, primary cells, and multiplex cytokine assay kits, as well as professional CRO services to fully meet the diverse needs of biomedical research and related fields.
For more information about Cloud-Clone Corp, visit www.cloud-clone.com.

CLOUD-CLONE CORP.(CCC)
Tel: 001-832-538-0970, 0086-27-8425-9552
Email: mail@cloud-clone.com, sales@cloud-clone.us

Visit us on social media:
LinkedIn: https://www.linkedin.com/company/cloud-clone-corp/
Instagram: https://www.instagram.com/cloudclonecorp2023/
TickTok: https://www.tiktok.com/@cloudclonecorp2026

SuKi Duan
CLOUD-CLONE CORP.WUHAN
Visit us on social media:
LinkedIn
Instagram
TikTok
X

This press release can be viewed online at: https://www.einpresswire.com/article/950850801

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.